Compare Funko Inc (FNKO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Merck & Co., Inc. — how do they compare? Funko Inc trades at $6.58 (market cap $363.97M), while Merck & Co., Inc. trades at $145.1 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 965.1× Funko Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Funko Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Merck & Co., Inc. for 98 Days on average.
| FNKO | MRK | |
|---|---|---|
Market Cap | $363.97M | $351.28B |
Volume | 1,422,651 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $156.43 |
52-Week Low | $2.81 | $82.49 |
Typical Hold Time | 33 Days | 98 Days |
Enterprise Value | $584.62M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.31, up 3.27% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 EBITDA guidance to $105M. Revenue declined to $908M in 2025 but shows stabilization with 2026 projections at $933M. Analyst consensus is mixed with 42.9% buy ratings and $7.58 price target, representing 20% upside potential.
Investment opportunity centers on turnaround execution with improving margins and debt reduction. Key risks include negative net income margins, competitive pressures in collectibles, and sensitivity to consumer discretionary spending. The stock offers value with low P/S of 0.38x but requires sustained profitability improvement to justify higher valuations.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
